20 Healthcare Stocks Moving In Monday's Pre-Market Session

Gainers

• Anixa Biosciences, Inc. ANIX stock moved upwards by 62.09% to $2.95 during Monday's pre-market session. The most recent rating by Aegis Capital, on Mar 23, is at Buy, with a price target of $8.

• Tiziana Life Sciences, Inc. TLSA stock increased by 27.66% to $3.60.

• Curis, Inc. CRIS shares rose 17.65% to $1.

• KemPharm, Inc. KMPH shares moved upwards by 17.09% to $0.37.

• Acorda Therapeutics, Inc. ACOR stock increased by 15.42% to $1.03.

• Mereo BioPharma Group, Inc. MREO shares rose 12.93% to $1.31.

• Midatech Pharma, Inc. MTP shares increased by 12.72% to $3.81.

• Pluristem Therapeutics, Inc. PSTI stock moved upwards by 10.46% to $9.29.

• Agile Therapeutics, Inc. AGRX stock rose 10.11% to $3.05. The most recent rating by H.C. Wainwright, on Mar 20, is at Buy, with a price target of $6.

• Co-Diagnostics, Inc. CODX shares rose 9.87% to $14.80. According to the most recent rating by Maxim Group, on Mar 3, the current rating is at Hold.

Losers

• Medigus, Inc. MDGS stock declined 18.03% to $2.91 during Monday's pre-market session.

• Celyad, Inc. CYAD stock declined 9.83% to $8.71. The most recent rating by Wells Fargo, on Mar 26, is at Overweight, with a price target of $20.

• Innate Pharma, Inc. IPHA stock decreased by 8.95% to $6.92.

• GenMark Diagnostics, Inc. GNMK stock declined 8.73% to $11.50. The most recent rating by Needham, on Mar 3, is at Buy, with a price target of $11.

• ViewRay, Inc. VRAY stock fell 6.32% to $1.78. The most recent rating by Oppenheimer, on May 1, is at Outperform, with a price target of $3.

• Milestone Pharmaceuticals, Inc. MIST shares declined 5.54% to $3.75. According to the most recent rating by Jefferies, on Mar 25, the current rating is at Hold.

• Millendo Therapeutics, Inc. MLND shares decreased by 5.41% to $1.75. The most recent rating by Oppenheimer, on Apr 7, is at Perform, with a price target of $2.

• VBI Vaccines, Inc. VBIV shares fell 5.17% to $1.10.

• SmileDirectClub, Inc. SDC stock fell 5.04% to $6.60. The most recent rating by UBS, on Mar 2, is at Neutral, with a price target of $9.

• Ritter Pharmaceuticals, Inc. RTTR shares decreased by 5.04% to $0.36.